Search Results - "Lanfiuti Baldi, P."

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience by Parisi, A., Palluzzi, E., Cortellini, A., Sidoni, T., Cocciolone, V., Lanfiuti Baldi, P., Porzio, G., Ficorella, C., Cannita, K.

“…One of the major challenges related to solvent-based taxanes administration in clinical practice is the high rate of hypersensitivity reactions (HSRs)…”
Get full text

Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study by MORELLI, M. F, SANTOMAGGIO, A, GUGLIELMI, F, MARTELLA, F, LANFIUTI BALDI, P, PORZIO, G, RUSSO, A, GEBBIA, N, IACOBELLI, S, MARCHETTI, P, FICORELLA, C, RICEVUTO, E, CANNITA, K, DE GALITIIS, F, TUDINI, M, BRUERA, G, MANCINI, M, PELLICCIONE, M, CALISTA, F

“…A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a…”
Get full text

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity by CIANCI, G, MORELLI, M. F, CANNITA, K, MORESE, R, RICEVUTO, E, DI ROCCO, Z. C, PORZIO, G, LANFIUTI BALDI, P, FICORELLA, C

“…At present, the various mechanisms involved in 5-fluorouracil (5-FU)-correlated cardiotoxicity remain to be elucidated and a universally accepted prophylaxis…”
Get full text

Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen by Cortellini, A., Parisi, A., Cannita, K., Venditti, O., Pavese, F., D'Orazio, C., Lanfiuti Baldi, P., Vicentini, V., Vicentini, R., Porzio, G., Verna, L., Ficorella, C.

Get full text

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil docetaxel regimen in metastatic breast cancer: a dose-finding study by FICORELLA, C, MORELLI, M. F, DE GALITIIS, F, CALISTA, F, MARCHETTI, P, RICEVUTO, E, CANNITA, K, PORZIO, G, LANFIUTI BALDI, P, CIANCI, G, DI ROCCO, Z. C, NATOLI, C, TINARI, N

“…A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00-10:00)…”
Get full text

P043 Bevacizumab/paclitaxel as first line therapy for metastatic breast cancer: new schedule in real life by Cannita, K, Paradisi, S, Cocciolone, V, Rinaldi, L, Lanfiuti-Baldi, P, Irelli, A, Cortellini, A, Bruera, G, Ricevuto, E, Ficorella, C

Get full text

P-136Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen by Cortellini, A, Parisi, A, Cannita, K, Venditti, O, Pavese, F, D'Orazio, C, Lanfiuti Baldi, P, Vicentini, V, Vicentini, R, Porzio, G, Verna, L, Ficorella, C

Get full text

Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice by Cortellini, A., Bruera, G., Sarno, I., Lanfiuti Baldi, P., Cannita, K., Dal Mas, A., Marchetti, A., Ficorella, C., Ricevuto, E.

Get full text

Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life by Rinaldi, L., Cannita, K., Cocciolone, V., Lanfiuti Baldi, P., Irelli, A., Paradisi, S., Bruera, G., Cortellini, A., Ficorella, C., Ricevuto, E.

Get full text

1633 - Bisphosphonates in Bone Metastatic Patients: Experience of Medical Oncology, University of L'Aquila Over 17 Years by Ricevuto, E., Irelli, A., Cannita, K., Bruera, G., Baldi, P. Lanfiuti, Cocciolone, V., Palluzzi, E., Rinaldi, L., Teti, A., Ficorella, C.

“…Three hundred and twenty-nine bone metastatic patients (BMP) followed at Medical Oncology Division, San Salvatore Hospital L'Aquila from 1995 were evaluated…”
Get full text

Bisphosphonates in Bone Metastatic Patients: Experience of Medical Oncology, University of L'Aquila Over 17 Years by Ricevuto, E., Irelli, A., Cannita, K., Bruera, G., Baldi, P. Lanfiuti, Cocciolone, V., Palluzzi, E., Rinaldi, L., Teti, A., Ficorella, C.

Get full text

Effectiveness of FIr-B/FOx and liver metastasectomies in liver-only metastatic colorectal cancer (MCRC) by Bruera, G., Cannita, K., Lanfiuti Baldi, P., Santomaggio, A., Marchetti, P., Nuzzo, G., Antonucci, A., Ficorella, C., Ricevuto, E.

“…Abstract only 582 Background: Effectiveness of liver metastasectomies was evaluated in liver-MCRC patients treated with FIr-B/FOx association in a previous…”
Get full text

Clinical properness of poker schedule weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-B/FOx) in young-elderly metastatic colorectal cancer (MCRC) by Bruera, G., Santomaggio, A., Cannita, K., Lanfiuti Baldi, P., Tudini, M., De Galitiis, F., Marchetti, P., Antonucci, A., Ficorella, C., Ricevuto, E.

“…Abstract only…”
Get full text

“Poker” schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study by Santomaggio, A., Ricevuto, E., Cannita, K., Bruera, G., Tudini, M., Lanfiuti Baldi, P., Mancini, M., Porzio, G., Marchetti, P., Ficorella, C.

“…Abstract only 4125 Background: Triplet combinations associating antimetabolites with irinotecan (CPT-11) and/or oxaliplatin (OHP) and/or bevacizumab (BEV) show…”
Get full text

The safety of dose-dense liposomal-encapsulated doxorubicin in association with docetaxel (MyTax) in breast cancer by Mancini, M, Cannita, K, Santomaggio, A, Tudini, M, De Galitiis, F, Morelli, M, Rispoli, A, Martella, F, Porzio, G, Pelliccione, M, Cocciolone, V, Lanfiuti Baldi, P, Penco, M, Romano, S, Fratini, S, Stifani, G, Marchetti, P, Ficorella, C, Ricevuto, E

“…Abstract Abstract #2157 Background: Liposomal-Encapsulated Doxorubicin (LED) shows equivalent efficacy, better cardiac tolerability at higher cumulative dose…”
Get full text